Pat(i)ent Rights
A waiver of intellectual property rights on Covid-19 vaccines and drugs alone may not benefit developing countries including India in the battle against the deadly disease. Murali Neelakantan, Former Global General Counsel of Cipla and Glenmark, and Vikas Dandekar, Editor, Pharma and Healthcare, ET Prime, explain…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The Morning Brief
See all episodes →
Similar episodes from other shows
More like The Morning Brief →
Exposing a Pharma secret: Evergreening!
US to support temporary suspension of Covid-19 vaccine patents, India’s coronavirus crisis is affecting global shipping
India's data privacy bill may infringe on your freedom of choice
When price caps on pharma drugs fail
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.